Enhanced Protection with
β-Lactamase Inhibition
℞ - Amoxycillin and Potassium Clavulanate Tablets IP 625 mg
Paxclav® 625 is a broad-spectrum antibiotic combining Amoxycillin with Potassium Clavulanate to deliver reliable antibacterial coverage, including activity against β-lactamase–producing organisms. It is indicated for the treatment of a wide range of bacterial infections where resistance may compromise standard penicillin therapy.
- Respiratory tract infections
- Ear, nose, and throat infections
- Urinary tract infections
- Skin and soft tissue infections
- Dental infections
- Bone and joint infections
Paxclav® 625 is formulated to overcome bacterial resistance mechanisms by protecting amoxycillin from enzymatic degradation. This combination restores and enhances antibacterial efficacy, ensuring dependable infection control across multiple organ systems.
Why Paxclav® 625
◉ β-lactamase inhibition restores amoxycillin activity
◉ Broader antibacterial spectrum than amoxycillin alone
◉ Effective against resistant bacterial strains
◉ Reduces risk of treatment failure and relapse
◉ Widely accepted first-line antibiotic combination
Mechanism of Action
Paxclav® 625 works through a synergistic antibacterial mechanism:
◉ Amoxycillin
A β-lactam antibiotic that inhibits bacterial cell wall synthesis, leading to bacterial cell death.
◉ Clavulanic Acid
A β-lactamase inhibitor that protects amoxycillin from enzymatic degradation, restoring and enhancing its antibacterial activity.
Key Clinical Advantages
◉ Expanded antibacterial spectrum
◉ Effective against resistant infections
◉ Helps reduce treatment failure rates
◉ Suitable for infections across multiple systems
◉ Widely accepted and trusted antibiotic combination
Dosage & Administration
Dosage:
As directed by the physician.
Administration:
Preferably taken after meals.
Schedule H Prescription Drug – Caution
Not to be sold by retail without the prescription of a Registered Medical Practitioner.
